Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Apr 1;5(2):a003434.
doi: 10.1101/mcs.a003434. Print 2019 Apr.

Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report

Elena V Poddubskaya  1   2 , Madina P Baranova  1   3 , Daria O Allina  4 , Marina I Sekacheva  2 , Lyudmila A Makovskaia  5 , Dmitriy E Kamashev  2 , Maria V Suntsova  6 , Viktoria S Barbara  7 , Irina N Kochergina-Nikitskaya  8 , Alexey A Aleshin  9
Affiliations
Case Reports

Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report

Elena V Poddubskaya et al. Cold Spring Harb Mol Case Stud. .

Abstract

Ovarian cancer is the fifth leading cause of cancer-related female mortality and the most lethal gynecological cancer. In this report, we present a rare case of recurrent granulosa cell tumor (GCT) of the ovary. We describe the case of a 26-yr-old woman with progressive GCT of the right ovary despite multiple lines of therapy who underwent salvage therapy selection based on a novel bioinformatical decision support tool (Oncobox). This analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient's disease.

Keywords: ovarian neoplasm.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A) Hematoxylin and eosin staining shows granulosa cell ovarian cancer (magnification, 200×); (B) c-Kit IHC (Cell Marque, YR145) demonstrated the tumor cells to be negative; (C) calretinin (marker of ovarian sex cord-stromal tumor) IHC (Roche, Ventana, SP65) demonstrated the tumor cells to be positive; (D) inhibin (marker of ovarian sex cord-stromal tumor) IHC (Cell Marque, R1) demonstrated the tumor cells to be positive.
Figure 2.
Figure 2.
The ERK signaling pathway was hyperactivated in the patient's tumor tissue. Visualization was provided by the Oncobox software. The pathway is shown as an interacting network, where green arrows indicate activation, and red arrows indicate inhibition. The color depth of each node of the network corresponds to the logarithms of the case-to-normal (CNR) expression rate for each node, in which “normal” is a geometric average between normal tissue samples; the scale represents the extent of up-/down-regulation. The molecular targets of imatinib are shown by black arrows.
Figure 3.
Figure 3.
Cystic-solid neoplasm on the lower contour of the liver (neoplasm #1). (A) MRI from 03.2016; (B) MRI from 06.2016; (C) MRI from 09.2016; (D) MRI from 10.2017; (E) MRI from 03.2018.
Figure 4.
Figure 4.
Cystic-solid multinodular formation in Douglas space, part of nodules with high-density content (Neoplasm #2). (А) MRI from 03.2016; (B) MRI from 06.2016; (C) MRI from 09.2016; (D) MRI from 03.2018.
Figure 5.
Figure 5.
Cystic-solid neoplasm with tuberous contours in the right lateral channel (neoplasm #3). (А) MRI from 03.2016; (B) RI from 06.201; (C) MRI from 09.2016; (D) MRI from 10.2017; (E) MRI from 03.2018.
See this image and copyright information in PMC

References

    1. Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G, Farooki A. 2013. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 37: 790–794. 10.1016/j.leukres.2013.02.005 - DOI - PubMed
    1. Bridgewater JA, Rustin GJS. 1999. Management of non-epithelial ovarian tumours. Oncology 57: 89–98. 10.1159/000012014 - DOI - PubMed
    1. Chu S, Alexiadis M, Fuller PJ. 2008. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol 108: 182–190. 10.1016/j.ygyno.2007.09.017 - DOI - PubMed
    1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–480. 10.1056/NEJMoa020461 - DOI - PubMed
    1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. 2001. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042. 10.1056/NEJM200104053441402 - DOI - PubMed

Publication types

Substances

Supplementary concepts